PRTA Stock Forecast 2025-2026
Distance to PRTA Price Targets
PRTA Price Momentum
10 Quality Stocks Worth Considering Now
Researching Prothena (PRTA) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on PRTA and similar high-potential opportunities.
Latest PRTA Stock Price Targets & Analyst Predictions
Based on our analysis of 19 Wall Street analysts, PRTA has a bullish consensus with a median price target of $44.00 (ranging from $20.00 to $110.00). The overall analyst rating is Strong Buy (8.6/10). Currently trading at $13.74, the median forecast implies a 220.2% upside. This outlook is supported by 8 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yasmeen Rahimi at Piper Sandler, projecting a 700.6% upside. Conversely, the most conservative target is provided by Brian Abrahams at RBC Capital, suggesting a 45.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PRTA Analyst Ratings
PRTA Price Target Range
Latest PRTA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PRTA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 26, 2025 | Piper Sandler | Yasmeen Rahimi | Overweight | Maintains | $110.00 |
| Feb 24, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $48.00 |
| Feb 21, 2025 | RBC Capital | Brian Abrahams | Sector Perform | Maintains | $20.00 |
| Feb 21, 2025 | Cantor Fitzgerald | Eric Schmidt | Overweight | Reiterates | $0.00 |
| Feb 21, 2025 | Chardan Capital | Rudy Li | Buy | Maintains | $40.00 |
| Feb 21, 2025 | Citizens Capital Markets | Jason Butler | Market Outperform | Reiterates | $80.00 |
| Feb 21, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $48.00 |
| Feb 7, 2025 | Oppenheimer | Jay Olson | Outperform | Maintains | $62.00 |
| Dec 20, 2024 | Chardan Capital | Rudy Li | Buy | Initiates | $40.00 |
| Dec 20, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $48.00 |
| Dec 19, 2024 | B of A Securities | Tazeen Ahmad | Neutral | Maintains | $22.00 |
| Nov 13, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $84.00 |
| Oct 1, 2024 | B of A Securities | Tazeen Ahmad | Neutral | Maintains | $31.00 |
| Oct 1, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $84.00 |
| Sep 30, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $0.00 |
| Aug 14, 2024 | Oppenheimer | Jay Olson | Outperform | Maintains | $62.00 |
| Aug 12, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $0.00 |
| Aug 9, 2024 | RBC Capital | Brian Abrahams | Sector Perform | Maintains | $24.00 |
| Jun 26, 2024 | RBC Capital | Brian Abrahams | Sector Perform | Reiterates | $28.00 |
| May 9, 2024 | JMP Securities | Jason Butler | Market Outperform | Maintains | $83.00 |
Prothena Corporation plc (PRTA) Competitors
The following stocks are similar to Prothena based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Prothena Corporation plc (PRTA) Financial Data
Prothena Corporation plc has a market capitalization of $739.58M with a P/E ratio of -6.1x. The company generates $135.16M in trailing twelve-month revenue with a -90.5% profit margin.
Revenue growth is +571.8% quarter-over-quarter, while maintaining an operating margin of -3,056.9% and return on equity of -23.3%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Prothena Corporation plc (PRTA) Business Model
About Prothena Corporation plc
Develops therapies for neurodegenerative diseases.
Prothena Corporation generates revenue through the discovery and development of novel therapies aimed at treating neurodegenerative diseases, such as Alzheimer's and Parkinson's. The company leverages partnerships and collaborations with biopharmaceutical firms to enhance its research capabilities and expedite the clinical development of its drug candidates.
Prothena focuses on addressing significant unmet medical needs by targeting pathogenic proteins involved in neurodegeneration. The company's robust pipeline and commitment to scientific innovation position it as a vital entity in the medical biotechnology landscape, with the potential to improve patient outcomes globally.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
163
CEO
Dr. Gene G. Kinney Ph.D.
Country
Ireland
IPO Year
2012
Website
www.prothena.comProthena Corporation plc (PRTA) Latest News & Analysis
PRTA reported a larger-than-expected fourth-quarter loss but indicated positive developments in its pipeline progress.
PRTA's wider loss may raise concerns about financial health, but positive pipeline developments could signal future growth potential, impacting stock valuation and investor sentiment.
Prothena Corporation will host its Q4 2024 earnings call on February 20, 2025, at 4:30 PM ET, featuring key executives and analysts from various financial institutions.
The Q4 earnings call provides insights into Prothena's financial performance and strategic direction, which can influence stock price and investor sentiment.
Prothena announced its Q4 and full year 2024 financial results, along with business highlights and guidance for 2025.
Prothena’s Q4 and full-year results, along with 2025 guidance, can influence stock performance and investor sentiment, impacting valuation and investment decisions.
Prothena (PRTA) reported a quarterly loss of $1.08 per share, worse than the expected loss of $1.02, but an improvement from a loss of $1.26 per share a year prior.
Prothena's larger-than-expected quarterly loss signals potential operational challenges, affecting investor sentiment and stock performance. The year-over-year improvement may not outweigh current worries.
Kuehn Law is investigating Prothena Corporation's officers and directors for potential breaches of fiduciary duty and self-dealing, which may lead to shareholder damages and governance reforms.
Allegations of fiduciary breaches and potential self-dealing at Prothena Corporation could lead to financial penalties and governance changes, impacting stock performance and investor confidence.
Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
1 month agoProthena will release its Q4 and full-year 2024 financial results on February 20, 2025.
Prothena's Q4 and full year 2024 financial results announcement date may impact stock performance and investor sentiment, influencing trading decisions ahead of the report.
Frequently Asked Questions About PRTA Stock
What is Prothena Corporation plc's (PRTA) stock forecast for 2025?
Based on our analysis of 19 Wall Street analysts, Prothena Corporation plc (PRTA) has a median price target of $44.00. The highest price target is $110.00 and the lowest is $20.00.
Is PRTA stock a good investment in 2025?
According to current analyst ratings, PRTA has 8 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $13.74. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PRTA stock?
Wall Street analysts predict PRTA stock could reach $44.00 in the next 12 months. This represents a 220.2% increase from the current price of $13.74. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Prothena Corporation plc's business model?
Prothena Corporation generates revenue through the discovery and development of novel therapies aimed at treating neurodegenerative diseases, such as Alzheimer's and Parkinson's. The company leverages partnerships and collaborations with biopharmaceutical firms to enhance its research capabilities and expedite the clinical development of its drug candidates.
What is the highest forecasted price for PRTA Prothena Corporation plc?
The highest price target for PRTA is $110.00 from Yasmeen Rahimi at Piper Sandler, which represents a 700.6% increase from the current price of $13.74.
What is the lowest forecasted price for PRTA Prothena Corporation plc?
The lowest price target for PRTA is $20.00 from Brian Abrahams at RBC Capital, which represents a 45.6% increase from the current price of $13.74.
What is the overall PRTA consensus from analysts for Prothena Corporation plc?
The overall analyst consensus for PRTA is bullish. Out of 19 Wall Street analysts, 8 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $44.00.
How accurate are PRTA stock price projections?
Stock price projections, including those for Prothena Corporation plc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
